A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly
PHASE3CompletedINTERVENTIONAL
Enrollment
1,024
Participants
Timeline
Start Date
April 15, 2019
Primary Completion Date
December 2, 2019
Study Completion Date
December 2, 2019
Conditions
Respiratory Tract Infections
Interventions
DRUG
Dactolisib
TORC1 inhibitor
OTHER
Placebo
Placebo
Trial Locations (1)
Unknown
P3 Research Ltd., Wellington
All Listed Sponsors
lead
Restorbio Inc.
INDUSTRY
NCT04668352 - A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly | Biotech Hunter | Biotech Hunter